General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson & Gotzsche, 2001). The high placebo response has been shown to be increasing as time progresses (Kemp et al., 2010; Loebel et al., 2010; Rief et al., 2009; Tuttle et al., 2015), with such ramifications as several pharma companies reducing or closing their psychiatric as well as general medicine R&D, increased costs for drug development, more inconclusive and failed trials, and delays in the development of new medications (Alphs et al., 2012).
News at CenExel
Taming the Placebo Effect in Depression Clinical Trials: The Methodological Implementation of a Placebo-Control Reminder Script
CenExel is proud to highlight the poster presented at the Annual International Society for CNS Clinical Trials and Methodology (ISCTM) Meeting, February 2019, Washington, DC. ABSTRACT Introduction: Although the placebo effect continues to persist within depressive...
A First-Time Investigation of a Subject Intervention to Reduce the Placebo and Nocebo Effects: A Multicenter, Randomized, Single-Blind, All Placebo Study of a Placebo-Control Reminder Script for Subjects with Major Depression
CenExel is proud to highlight the poster presented at the Annual CNS Summit Meeting, November 2018, Boca Raton, FL. ABSTRACT Introduction: This investigation is the first known that empirically explores if educating subjects about key causes of the placebo effect...
Can Subjects With Major Depression Learn About Key Placebo Response Factors? The Effect of an Educational Placebo Response Video
CenExel is proud to highlight the poster presented at the Annual Meeting of the International Society for CNS Clinical Trials and Methodology Conference, February 2018, Washington, DC. ABSTRACT Introduction: The challenge to reliably achieve signal detection in...